https://www.selleckchem.com/pr....oducts/gilteritinib-
et obtained a more noticeable position with the child growth. Regulatory agencies in the European Union (EU) and in the United States of America (USA) have adapted and launched regulatory pathways to accelerate patient access to innovative therapies, such as advanced therapy medicinal products (ATMPs). The aim of this study is to analyze similarities and differences between regulatory pathways followed by the approved ATMPs in both regions. A retrospective analysis of the ATMPs approved by EU and US regulatory agencies was
Gefällt mir
Kommentar
Teilen
